Apple Tree Partners related stories
All articles and analysis
Aurinia nets $52 mln to develop treatment for lupus nephritisAurinia Pharmaceuticals Inc (TSX-V: AUP) has completed a US$52 million private placement. The deal was led by venBio, New Enterprise Associates, Redmile Group, RA Capital Management, Great Point Partners and Apple Tree Partners, with the participation of existing investors Lumira Capital, ILJIN Life Science and Difference Capital. Lumira, Difference Capital and ILJIN in 2013 helped finance Aurinia's merger /canada/2013/09/24/isotechnika-aurinia-merger-completed-6-mln-investment/ with Isotechnika Pharma Inc. The Edmonton-based company intends to use the new funds for the clinical and non-clinical development of its lead drug candidate, a therapy for treating lupus nephritis. Aurinia's current leadership team includes former senior managers of Aspreva Pharmaceuticals Corp, which was acquired in 2008.
Aileron Therapeutics secures new financingAileron Therapeutics has secured $30 million in Series E equity financing from investors including Apple Tree Partners, Roche Venture Fund, Novartis Venture Funds, Lilly Ventures, SR One and Excel Venture Management. The clinical stage biopharmaceutical company is developing therapeutics based on its proprietary Stapled Peptide drug platform.
- Tokai Pharmaceuticals Inks $35.5m Series E
Tokai Pharmaceuticals, a biopharmaceutical company focused on developing new treatments for prostate cancer, has raised $35.5 million in a Series E financing. The financing round included both current investors, Apple Tree Partners and Novartis Venture Funds, as well as undisclosed angel investors.
- Tokai Pharmaceuticals Inks $23M
Tokai Pharmaceuticals, a biopharmaceutical company focused on treatment for prostate cancer, has closed a $23 million Series D3 financing round. The money will support clinical development of the company’s lead drug candidate. Existing shareholders Novartis Venture Fund and Apple Tree Partners provided the financing. Tokai is based in Cambridge, Mass.
Small Fund, Big Dream: Apple Tree PartnersApple Tree Partners has grown into its own after branching off from Oak Investment Partners
- Exit watch, week of Dec. 14, 2009
News briefs about portfolio companies sold in the past week
- Celgene Buying Gloucester Pharma For Up To $640 Million
Celgene Corp. (Nasdaq: CELG) has agreed to acquire Gloucester Pharmaceuticals, a Cambridge, Mass.-based developer of oncology drugs. The deal is valued at up to $640 million, including a $340 million up-front cash payment and up to $300 million in earn-outs. Gloucester Pharma had raised over $130 million in VC funding, from firms like Apple Tree Partners, Novo AS, ProQuest Investments, Prospect Venture Partners and Rho Ventures.
- peHUB Wire: Monday, December 7, 2009
Random Ramblings
- peHUB Wire: Monday, December 7, 2009
Random Ramblings